Back to top
more

QIAGEN (QGEN)

(Delayed Data from NYSE)

$42.98 USD

42.98
1,317,948

+0.30 (0.70%)

Updated May 3, 2024 04:00 PM ET

After-Market: $42.99 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (80 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for QGEN

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

QIAGEN N.V. [QGEN]

Reports for Purchase

Showing records 221 - 234 ( 234 total )

Company: QIAGEN N.V.

Industry: Medical - Biomedical and Genetics

Record: 221

04/27/2012

Company Report

Pages: 10

1Q12 Results Top Street''s Low Expectations

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: QIAGEN N.V.

Industry: Medical - Biomedical and Genetics

Record: 222

04/26/2012

Daily Note

Pages: 8

1Q12 First Blush - Decent Top line and EPS Beat vs Consensus - GMs and R&D Better, But SG&A Bloated - Broad Geographic Growth - Staying NEUTRAL

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: QIAGEN N.V.

Industry: Medical - Biomedical and Genetics

Record: 223

04/24/2012

Company Report

Pages: 8

1Q12 Financial Preview - Anticipating Slightly Better Results Driven by Personalized Medicine - Still Skeptical on Full Year - Reaffirming NEUTRAL

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: QIAGEN N.V.

Industry: Medical - Biomedical and Genetics

Record: 224

02/01/2012

Company Report

Pages: 10

Ok 4Q11 Results Cap Off a Rebuilding Year - Guidance on the Soft Side

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: QIAGEN N.V.

Industry: Medical - Biomedical and Genetics

Record: 225

01/31/2012

Daily Note

Pages: 8

4Q11 First Blush - Consumables Strength Drives Solid Top Line Beat - EPS Beat Less Impressive - 2012 Guidance a Little Light

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: QIAGEN N.V.

Industry: Medical - Biomedical and Genetics

Record: 226

01/30/2012

Company Report

Pages: 8

4Q11 Financial Preview - Expecting Slightly Lower Results - Cautious on HPV Despite North American 4Q11 Tender - No Compelling Reason To Own Here

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: QIAGEN N.V.

Industry: Medical - Biomedical and Genetics

Record: 227

11/04/2011

Company Report

Pages: 11

3Q11 Final Recap - Reaffirming NEUTRAL

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: QIAGEN N.V.

Industry: Medical - Biomedical and Genetics

Record: 228

11/03/2011

Daily Note

Pages: 8

3Q11 First Blush - Lackluster Results - Topline Just Shy on HPV Order Distortion in North America -System Sales Solid - Other Income Drives EPS Beat

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: QIAGEN N.V.

Industry: Medical - Biomedical and Genetics

Record: 229

11/02/2011

Company Report

Pages: 7

3Q11 Preview - Expecting Results to Edge Past Consensus - Trimming Estimates and PT on More Challenging Macro & GPRO HPV Approval

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: QIAGEN N.V.

Industry: Medical - Biomedical and Genetics

Record: 230

07/27/2011

Company Report

Pages: 10

2Q11 Results Slightly Better

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: QIAGEN N.V.

Industry: Medical - Biomedical and Genetics

Record: 231

07/25/2011

Company Report

Pages: 8

Expecting in-line 2Q11 results.

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: QIAGEN N.V.

Industry: Medical - Biomedical and Genetics

Record: 232

04/29/2011

Company Report

Pages: 10

1Q11 Report Ok; More Positives Than Negatives; 2011 Tailwinds Intact; Back Half Acceleration

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 25.00

Research Provided by a Third Party

Company: QIAGEN N.V.

Industry: Medical - Biomedical and Genetics

Record: 233

04/05/2011

Company Report

Pages: 24

Assuming Coverage with an OUTPERFORM & $24 PT

Provider: WEDBUSH SECURITIES INC.

Analyst: KHURSHID Z

Price: 75.00

Research Provided by a Third Party

Company: QIAGEN N.V.

Industry: Medical - Biomedical and Genetics

Record: 234

02/09/2010

Company Report

Pages: 2

Provider: Zacks Investment Research

Analyst: ZENG G

Price: 24.95

Research Provided by a Third Party